Patents by Inventor Daniel D. Long

Daniel D. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5 to 7 membered heterocyclic amides as JAK inhibitors
    Patent number: 10836763
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 17, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20200339580
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 29, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 10745394
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Ioanna Stergiades, Priscilla M. Van Dyke
  • Glucuronide prodrugs of Janus kinase inhibitors
    Patent number: 10745405
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Donna A. A. Wilton, Mandy M. Loo, Ryan Hudson, Patrick J. Brassil
  • Prodrugs of fencamfamine
    Patent number: 10662146
    Abstract: Disclosed herein are pharmaceutical compositions with fencamfamine or fencamfamine related prodrug derivatives. The pharmaceutical compositions are for targeted therapeutic applications including, but not limited to, treating cancer-related fatigue, apathy in Alzheimer's Disease, major depression, and attention deficit-hyperactivity disorder. Also disclosed are methods of synthesizing the pharmaceutical compositions with fencamfamine or fencamfamine related prodrug derivatives.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: May 26, 2020
    Assignee: PRAXIS BIORESEARCH, LLC
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A. Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
  • 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS
    Publication number: 20200071325
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 5, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS
    Publication number: 20200071323
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 5, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease
    Publication number: 20190389895
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 26, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
  • Glucuronide prodrugs of tofacitinib
    Patent number: 10472366
    Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 12, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Donna A.A. Wilton, Mandy M. Loo
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20190308966
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Ioanna Stergiades, Priscilla M. Van Dyke
  • Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
    Patent number: 10435428
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 8, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 10377751
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: August 13, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20190119267
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: August 16, 2018
    Publication date: April 25, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades
  • Thiocarbamate prodrugs of tofacitinib
    Patent number: 10233174
    Abstract: The invention relates to thiocarbamate prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: wherein R1, R2, R3, R4 and n are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: March 19, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: Daniel D. Long
  • PRODRUGS OF FENCAMFAMINE
    Publication number: 20190023650
    Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
    Type: Application
    Filed: September 13, 2016
    Publication date: January 24, 2019
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A. Smith, Yuhua JI, Valentino Stella, Daniel D. Long, Daniel Marquess
  • THIOCARBAMATE PRODRUGS OF TOFACITINIB
    Publication number: 20180339980
    Abstract: The invention relates to thiocarbamate prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: wherein R1, R2, R3, R4 and n are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 29, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: DANIEL D. LONG
  • GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
    Publication number: 20180339990
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 29, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO, RYAN HUDSON, PATRICK J. BRASSIL
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 10081626
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: September 25, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • GLUCURONIDE PRODRUGS OF TOFACITINIB
    Publication number: 20180258094
    Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO
  • NEPRILYSIN INHIBITORS
    Publication number: 20180193338
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton